Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. on February 14, 2019. The report discloses a corporate event regarding the presentation of clinical trial data at the Genitourinary Cancers Symposium (ASCO-GU) in San Francisco, CA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than financial performance.
Material Changes and Events
On February 14, 2019, Trovagene, Inc. announced the presentation of an overview of its ongoing Phase 2 study. The study evaluates Onvansertib in combination with Zytiga (abiraterone acetate)/prednisone in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the inherent uncertainties of clinical trials. The primary disclosure is the scheduled presentation of clinical data.
Investor Verification Checklist
- Verify the date and location of the ASCO-GU presentation.
- Review the attached press release (Exhibit 99.1) for specific clinical data points and study endpoints.
- Confirm the current status of the Phase 2 study for Onvansertib in mCRPC patients.
- Check subsequent filings for the actual results of the study presentation.